About BridgeBio Pharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://bridgebio.com/
Frequently Asked Questions
What is the 52-week range for BBIO?
The 52-week high is $93.415 and the 52-week low is $51.85.
What is the P/E ratio for BBIO?
The P/E ratio data is currently unavailable.
What is the dividend yield for BBIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -206.74%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -97.03%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 150.71.
Analyst Recommendation Trends
Wall Street analyst consensus for BBIO over the last few months:
Latest BBIO News
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform
Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.
The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis
Earlier this week, BridgeBio Pharma reported peer-reviewed real-world data in Cardiology and Therapy showing that its ATTR cardiomyopathy therapy acoramidis was associated with lower early clinical worsening risk versus tafamidis in newly treated patients over a mean follow-up of 4.6 months. The study offers the first head-to-head, real-world comparison between approved transthyretin stabilizers, potentially strengthening the clinical and commercial positioning of acoramidis as Attruby in...
BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands
BridgeBio Pharma has delivered a strong share price run in recent years, and that kind of move naturally raises the question of whether the current valuation still lines up with the sales that sit behind the story. With fresh real world data around its acoramidis therapy now in the mix, investors are asking how much revenue power is realistically being priced into the stock today. Over the past 3 years the stock has gained 148.7%, which puts real pressure on the question of how much sales...
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion. Trimarchi said the company’s strategy centers on developing medicines for gen
Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence
ExxonMobil, ADP and Cadence highlight today's analyst reports, with growth drivers, market risks and strategic moves shaping their outlooks.
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2026 Update
Viking Globalâs Q2 2026 13F: top holdings, new Ferrari/MSCI stakes, and exits from Apple/Alphabet. See more details here.
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BridgeBio Pharma, Inc. (BBIO) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 9:40 AM EDTCompany...
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis - Acoramidis was also associated with a significant 43% r
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s r
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:00 AM EDTCompany ParticipantsChinmay Shukla -...
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:10 AM EDTCompany ParticipantsChinmay Shukla -...
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 1:30 PM EDTCompany ParticipantsChinmay Shukla - Senior Vice...
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events Stabilization of sleep apnea measures: The mean total Apnea-Hypopnea Index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group; in children younger than 8 years of age, the mean total AHI was u
BridgeBio's Oral Infigratinib Shows Reduced Sleep Apnea And Ear Infection Rates Beyond Growth Benefits In Phase 3 PROPEL 3 Trial At 52 Weeks
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media eventsStabilization of sleep
BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis?
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is asking investors to look beyond disease stabilization in transthyretin amyloid cardiomyopathy, or ATTR-CM. New cardiac magnetic resonance imaging data from the Phase 3 ATTRibute-CM study and its open-label extension suggested that some acoramidis-treated patients experienced improvements in cardiac structure and function. A separate post-hoc analysis found that treatment preserved more […]
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-17 | Kumar Neil | -1,279 | $69.5696 | $88,980 |
| 2026-09-17 | Kumar Neil | -8,721 | $69.0136 | $601,868 |
| 2026-08-19 | Kumar Neil | -100 | $85.65 | $8,565 |
| 2026-08-19 | Kumar Neil | -1,800 | $84.6867 | $152,436 |
| 2026-08-19 | Kumar Neil | -8,100 | $83.8588 | $679,256 |
| 2026-08-18 | Kumar Neil | -1,199 | $83.7732 | $100,444 |
| 2026-08-18 | Kumar Neil | -14,602 | $82.9922 | $1,211,852 |
| 2026-08-18 | Kumar Neil | -17,279 | $82.2104 | $1,420,514 |
| 2026-08-18 | Kumar Neil | -1,900 | $81.1494 | $154,184 |
| 2026-08-16 | Trimarchi Thomas | -22,781 | $79.86 | $1,819,291 |
| 2026-08-16 | Apuli Maricel | -4,714 | $79.86 | $376,460 |
| 2026-08-16 | Kumar Neil | -6,520 | - | - |
| 2026-08-16 | Kumar Neil | -11,554 | - | - |
| 2026-08-16 | Kumar Neil | -19,599 | - | - |
| 2026-08-16 | Kumar Neil | -33,544 | - | - |
| 2026-08-16 | Kumar Neil | -36,237 | $79.86 | $2,893,887 |
| 2026-08-16 | Kumar Neil | +6,520 | - | - |
| 2026-08-16 | Kumar Neil | +11,554 | - | - |
| 2026-08-16 | Kumar Neil | +19,599 | - | - |
| 2026-08-16 | Kumar Neil | +33,544 | - | - |
| 2026-07-30 | Apuli Maricel | -2,000 | $80.06 | $160,120 |
| 2026-07-09 | Ellis Andrea | -17,167 | - | - |
| 2026-07-09 | Ellis Andrea | -17,167 | $84 | $1,442,028 |
| 2026-07-09 | Ellis Andrea | +17,167 | $16.75 | $287,547 |
| 2026-07-09 | Cook Jennifer E. | -17,167 | - | - |
| 2026-07-09 | Cook Jennifer E. | -112,422 | - | - |
| 2026-07-09 | Cook Jennifer E. | -19,000 | - | - |
| 2026-07-09 | Cook Jennifer E. | -112,422 | $90 | $10,117,980 |
| 2026-07-09 | Cook Jennifer E. | -36,167 | $84 | $3,038,028 |
| 2026-07-09 | Cook Jennifer E. | +17,167 | $16.75 | $287,547 |
| 2026-07-09 | Cook Jennifer E. | +112,422 | $29 | $3,260,238 |
| 2026-07-09 | Cook Jennifer E. | +19,000 | $8.45 | $160,550 |
| 2026-06-24 | Cook Jennifer E. | -17,167 | - | - |
| 2026-06-24 | Cook Jennifer E. | -20,000 | - | - |
| 2026-06-24 | Cook Jennifer E. | -37,167 | $70 | $2,601,690 |
| 2026-06-24 | Cook Jennifer E. | +17,167 | $16.75 | $287,547 |
| 2026-06-24 | Cook Jennifer E. | +20,000 | $8.45 | $169,000 |
| 2026-06-23 | Cook Jennifer E. | -2,196 | $68.57 | $150,580 |
| 2026-06-23 | Valantine Hannah | -2,196 | $68.57 | $150,580 |
| 2026-06-22 | Cook Jennifer E. | +5,277 | - | - |
| 2026-06-22 | Cook Jennifer E. | +3,990 | - | - |
| 2026-06-22 | Valantine Hannah | -2,808 | - | - |
| 2026-06-22 | Valantine Hannah | +5,277 | - | - |
| 2026-06-22 | Valantine Hannah | -2,808 | $68 | $190,944 |
| 2026-06-22 | Valantine Hannah | +2,808 | $41.73 | $117,178 |
| 2026-06-22 | Valantine Hannah | +3,990 | - | - |
| 2026-06-22 | Ellis Andrea | +5,277 | - | - |
| 2026-06-22 | Ellis Andrea | +3,990 | - | - |
| 2026-06-22 | Lo Andrew | +5,277 | - | - |
| 2026-06-22 | Lo Andrew | +3,990 | - | - |
| 2026-06-22 | Dachille Douglas A. | +5,277 | - | - |
| 2026-06-22 | Dachille Douglas A. | +3,990 | - | - |
| 2026-06-22 | Satvat Ali J. | +5,277 | - | - |
| 2026-06-22 | Satvat Ali J. | +3,990 | - | - |
| 2026-06-22 | AGUIAR ERIC | +5,277 | - | - |
| 2026-06-22 | AGUIAR ERIC | +3,990 | - | - |
| 2026-06-22 | MCCORMICK FRANK | +5,277 | - | - |
| 2026-06-22 | MCCORMICK FRANK | +3,990 | - | - |
| 2026-06-22 | MOMTAZEE JAMES C | +5,277 | - | - |
| 2026-06-22 | MOMTAZEE JAMES C | +3,990 | - | - |
| 2026-06-22 | HOMCY CHARLES J | +5,277 | - | - |
| 2026-06-22 | HOMCY CHARLES J | +3,990 | - | - |
| 2026-06-22 | DANIELS RONALD J | +5,277 | - | - |
| 2026-06-22 | DANIELS RONALD J | +3,990 | - | - |
| 2026-06-22 | Hassan Fred | +5,277 | - | - |
| 2026-06-22 | Hassan Fred | +3,990 | - | - |
| 2026-06-20 | HOMCY CHARLES J | -788 | $66.27 | $52,221 |
| 2026-06-05 | Kumar Neil | -4,415 | $68.9593 | $304,455 |
| 2026-06-05 | Kumar Neil | -8,437 | $67.8848 | $572,744 |
| 2026-06-05 | Kumar Neil | -7,148 | $67.199 | $480,338 |
| 2026-06-05 | Kumar Neil | -4,416 | $68.9593 | $304,524 |
| 2026-06-05 | Kumar Neil | -8,437 | $67.8848 | $572,744 |
| 2026-06-05 | Kumar Neil | -7,147 | $67.199 | $480,271 |
| 2026-06-04 | Kumar Neil | -450 | $68.2697 | $30,721 |
| 2026-06-04 | Kumar Neil | -15,921 | $67.7377 | $1,078,452 |
| 2026-06-04 | Kumar Neil | -1,429 | $66.723 | $95,347 |
| 2026-06-04 | Kumar Neil | -2,200 | $65.7202 | $144,584 |
| 2026-06-04 | Kumar Neil | -450 | $68.2697 | $30,721 |
| 2026-06-04 | Kumar Neil | -15,921 | $67.7378 | $1,078,454 |
| 2026-06-04 | Kumar Neil | -1,429 | $66.723 | $95,347 |
| 2026-06-04 | Kumar Neil | -2,200 | $65.7202 | $144,584 |
| 2026-05-21 | Kumar Neil | -800 | $70.9189 | $56,735 |
| 2026-05-21 | Kumar Neil | -11,250 | $70.4814 | $792,916 |
| 2026-05-21 | Kumar Neil | -5,072 | $69.2235 | $351,102 |
| 2026-05-21 | Kumar Neil | -6,725 | $68.3025 | $459,334 |
| 2026-05-21 | Kumar Neil | -2,256 | $67.5687 | $152,435 |
| 2026-05-18 | Trimarchi Thomas | -3,195 | $65.9507 | $210,712 |
| 2026-05-18 | Trimarchi Thomas | -10,456 | $64.8151 | $677,707 |
| 2026-05-16 | Trimarchi Thomas | -22,781 | $66.13 | $1,506,508 |
| 2026-05-16 | Apuli Maricel | -4,714 | $66.13 | $311,737 |
| 2026-05-16 | Kumar Neil | -6,519 | - | - |
| 2026-05-16 | Kumar Neil | -11,553 | - | - |
| 2026-05-16 | Kumar Neil | -19,599 | - | - |
| 2026-05-16 | Kumar Neil | -33,544 | - | - |
| 2026-05-16 | Kumar Neil | -36,236 | $66.13 | $2,396,287 |
| 2026-05-16 | Kumar Neil | +6,519 | - | - |
| 2026-05-16 | Kumar Neil | +11,553 | - | - |
| 2026-05-16 | Kumar Neil | +19,599 | - | - |
| 2026-05-16 | Kumar Neil | +33,544 | - | - |
| 2026-05-15 | Scott Randal W. | -10,000 | - | - |
| 2026-05-15 | Scott Randal W. | -200 | $69.12 | $13,824 |
| 2026-05-15 | Scott Randal W. | -1,512 | $68.2303 | $103,164 |
| 2026-05-15 | Scott Randal W. | -2,088 | $67.5302 | $141,003 |
| 2026-05-15 | Scott Randal W. | -6,200 | $66.6878 | $413,464 |
| 2026-05-15 | Scott Randal W. | +10,000 | $16.75 | $167,500 |
| 2026-05-08 | Kumar Neil | -950 | $68.3477 | $64,930 |
| 2026-05-08 | Kumar Neil | -5,076 | $67.3455 | $341,846 |
| 2026-05-08 | Kumar Neil | -13,974 | $66.6505 | $931,374 |
| 2026-05-08 | Kumar Neil | -950 | $68.3477 | $64,930 |
| 2026-05-08 | Kumar Neil | -5,077 | $67.3455 | $341,913 |
| 2026-05-08 | Kumar Neil | -13,973 | $66.6505 | $931,307 |
| 2026-05-07 | Kumar Neil | -449 | $69.0911 | $31,022 |
| 2026-05-07 | Kumar Neil | -8,334 | $68.3775 | $569,858 |
| 2026-05-07 | Kumar Neil | -11,217 | $67.4949 | $757,090 |
| 2026-05-07 | Kumar Neil | -450 | $69.0911 | $31,091 |
| 2026-05-07 | Kumar Neil | -8,333 | $68.3775 | $569,790 |
| 2026-05-07 | Kumar Neil | -11,217 | $67.495 | $757,091 |
| 2026-04-30 | Apuli Maricel | -2,000 | $71.58 | $143,160 |
| 2026-04-10 | Kumar Neil | -20,000 | $74.6038 | $1,492,076 |
| 2026-04-10 | Kumar Neil | -20,000 | $74.6048 | $1,492,096 |
| 2026-04-09 | Kumar Neil | -7,800 | $75.5287 | $589,124 |
| 2026-04-09 | Kumar Neil | -5,128 | $74.5669 | $382,379 |
| 2026-04-09 | Kumar Neil | -7,072 | $73.6427 | $520,801 |
| 2026-04-09 | Kumar Neil | -7,500 | $75.5548 | $566,661 |
| 2026-04-09 | Kumar Neil | -5,300 | $74.6044 | $395,403 |
| 2026-04-09 | Kumar Neil | -7,200 | $73.6444 | $530,240 |
| 2026-03-18 | Trimarchi Thomas | +59,041 | - | - |
| 2026-03-18 | Apuli Maricel | +14,170 | - | - |
| 2026-03-17 | Kumar Neil | +104,313 | - | - |
| 2026-03-17 | Kumar Neil | +40,570 | - | - |
| 2026-03-13 | Kumar Neil | -9,759 | $69.2251 | $675,568 |
| 2026-03-13 | Kumar Neil | -10,241 | $68.3864 | $700,345 |
| 2026-03-13 | Kumar Neil | -10,310 | $69.1997 | $713,449 |
| 2026-03-13 | Kumar Neil | -9,690 | $68.3634 | $662,441 |
| 2026-03-12 | Kumar Neil | -300 | $70.15 | $21,045 |
| 2026-03-12 | Kumar Neil | -5,815 | $69.2913 | $402,929 |
| 2026-03-12 | Kumar Neil | -13,885 | $68.4686 | $950,687 |
| 2026-03-12 | Kumar Neil | -300 | $70.15 | $21,045 |
| 2026-03-12 | Kumar Neil | -5,363 | $69.3176 | $371,750 |
| 2026-03-12 | Kumar Neil | -14,337 | $68.4808 | $981,809 |
| 2026-03-10 | Valantine Hannah | -8,671 | - | - |
| 2026-03-10 | Valantine Hannah | -8,671 | $72 | $624,312 |
| 2026-03-10 | Valantine Hannah | +8,671 | $27.36 | $237,239 |
| 2026-03-04 | Ellis Andrea | -64,921 | - | - |
| 2026-03-04 | Ellis Andrea | -64,921 | $64.8681 | $4,211,302 |
| 2026-03-04 | Ellis Andrea | +64,921 | $8.45 | $548,582 |
| 2026-02-27 | Valantine Hannah | -25,484 | - | - |
| 2026-02-27 | Valantine Hannah | -10,900 | $67.8437 | $739,496 |
| 2026-02-27 | Valantine Hannah | -14,584 | $67.0793 | $978,285 |
| 2026-02-27 | Valantine Hannah | +25,484 | $48.45 | $1,234,700 |
| 2026-02-26 | Apuli Maricel | -2,000 | $66 | $132,000 |
| 2026-02-19 | Kumar Neil | -602 | $72.801 | $43,826 |
| 2026-02-19 | Kumar Neil | -8,528 | $72.0804 | $614,702 |
| 2026-02-19 | Kumar Neil | -18,923 | $71.0347 | $1,344,190 |
| 2026-02-17 | Apuli Maricel | -510 | $74.31 | $37,898 |
| 2026-02-17 | Trimarchi Thomas | -200 | $75.38 | $15,076 |
| 2026-02-17 | Trimarchi Thomas | -13,400 | $74.7068 | $1,001,071 |
| 2026-02-17 | Scott Randal W. | -10,000 | - | - |
| 2026-02-17 | Scott Randal W. | -3,307 | $75.9261 | $251,088 |
| 2026-02-17 | Scott Randal W. | -4,793 | $75.5725 | $362,219 |
| 2026-02-17 | Scott Randal W. | -1,900 | $74.3421 | $141,250 |
| 2026-02-17 | Scott Randal W. | +10,000 | $16.75 | $167,500 |
| 2026-02-16 | Apuli Maricel | -4,349 | $75.25 | $327,262 |
| 2026-02-16 | Trimarchi Thomas | -18,819 | $75.25 | $1,416,130 |
| 2026-02-16 | Kumar Neil | -11,554 | - | - |
| 2026-02-16 | Kumar Neil | -19,600 | - | - |
| 2026-02-16 | Kumar Neil | -33,544 | - | - |
| 2026-02-16 | Kumar Neil | -30,970 | $75.25 | $2,330,493 |
| 2026-02-16 | Kumar Neil | +11,554 | - | - |
| 2026-02-16 | Kumar Neil | +19,600 | - | - |
| 2026-02-16 | Kumar Neil | +33,544 | - | - |
| 2026-02-11 | Kumar Neil | -3,961 | $73.2505 | $290,145 |
| 2026-02-11 | Kumar Neil | -4,404 | $72.6472 | $319,938 |
| 2026-02-11 | Kumar Neil | -3,775 | $71.4581 | $269,754 |
| 2026-02-11 | Kumar Neil | -7,860 | $70.7005 | $555,706 |
| 2026-02-11 | Kumar Neil | -3,994 | $73.2535 | $292,574 |
| 2026-02-11 | Kumar Neil | -4,484 | $72.635 | $325,695 |
| 2026-02-11 | Kumar Neil | -3,716 | $71.4416 | $265,477 |
| 2026-02-11 | Kumar Neil | -7,806 | $70.6887 | $551,796 |
| 2026-02-10 | Kumar Neil | -5,960 | $72.2737 | $430,751 |
| 2026-02-10 | Kumar Neil | -14,040 | $71.7953 | $1,008,006 |
| 2026-02-10 | Kumar Neil | -5,799 | $72.2823 | $419,165 |
| 2026-02-10 | Kumar Neil | -14,201 | $71.8018 | $1,019,657 |
| 2026-01-09 | Kumar Neil | -1,855 | $78.1035 | $144,882 |
| 2026-01-09 | Kumar Neil | -10,677 | $77.4577 | $827,016 |
| 2026-01-09 | Kumar Neil | -6,067 | $76.527 | $464,289 |
| 2026-01-09 | Kumar Neil | -1,401 | $75.6088 | $105,928 |
| 2026-01-09 | Kumar Neil | -375 | $78.192 | $29,322 |
| 2026-01-09 | Kumar Neil | -10,519 | $77.6086 | $816,365 |
| 2026-01-09 | Kumar Neil | -6,955 | $76.7173 | $533,569 |
| 2026-01-09 | Kumar Neil | -2,151 | $75.752 | $162,943 |
| 2026-01-08 | Kumar Neil | -300 | $75.2033 | $22,561 |
| 2026-01-08 | Kumar Neil | -8,135 | $74.3775 | $605,061 |
| 2026-01-08 | Kumar Neil | -11,565 | $73.6542 | $851,811 |
| 2026-01-08 | Kumar Neil | -400 | $75.1602 | $30,064 |
| 2026-01-08 | Kumar Neil | -8,085 | $74.3773 | $601,340 |
| 2026-01-08 | Kumar Neil | -11,515 | $73.6446 | $848,018 |
| 2025-12-15 | Kumar Neil | -1,700 | $75.2412 | $127,910 |
| 2025-12-15 | Kumar Neil | -28,311 | $74.5997 | $2,111,992 |
| 2025-12-12 | Trimarchi Thomas | -13,826 | $75.15 | $1,039,024 |
| 2025-12-12 | Apuli Maricel | -2,003 | $75.15 | $150,525 |
| 2025-12-12 | Kumar Neil | -60,975 | - | - |
| 2025-12-12 | Kumar Neil | -30,964 | $75.15 | $2,326,945 |
| 2025-12-12 | Kumar Neil | +60,975 | - | - |
| 2025-12-08 | Apuli Maricel | -2,000 | $74.26 | $148,520 |
| 2025-12-05 | Kumar Neil | -7,712 | $73.7498 | $568,758 |
| 2025-12-05 | Kumar Neil | -12,288 | $73.0411 | $897,529 |
| 2025-12-05 | Kumar Neil | -7,483 | $73.7607 | $551,951 |
| 2025-12-05 | Kumar Neil | -12,517 | $73.0466 | $914,324 |
| 2025-12-04 | Kumar Neil | -5,700 | $74.7996 | $426,358 |
| 2025-12-04 | Kumar Neil | -12,200 | $74.4238 | $907,970 |
| 2025-12-04 | Kumar Neil | -2,100 | $73.1554 | $153,626 |
| 2025-12-04 | Kumar Neil | -5,708 | $74.7966 | $426,939 |
| 2025-12-04 | Kumar Neil | -12,192 | $74.4243 | $907,381 |
| 2025-12-04 | Kumar Neil | -2,100 | $73.1611 | $153,638 |
| 2025-11-20 | Kumar Neil | -5,456 | $66.7129 | $363,986 |
| 2025-11-20 | Kumar Neil | -14,299 | $65.904 | $942,361 |
| 2025-11-20 | Kumar Neil | -6,401 | $64.9706 | $415,877 |
| 2025-11-18 | Lo Andrew | -30,993 | $66.049 | $2,047,057 |
| 2025-11-18 | Lo Andrew | -24,007 | $65.2315 | $1,566,013 |
| 2025-11-17 | Lo Andrew | -3,798 | $67.056 | $254,679 |
| 2025-11-17 | Lo Andrew | -36,801 | $66.6263 | $2,451,914 |
| 2025-11-17 | Scott Randal W. | -10,000 | - | - |
| 2025-11-17 | Scott Randal W. | -6,199 | $66.8908 | $414,656 |
| 2025-11-17 | Scott Randal W. | -3,801 | $66.2481 | $251,809 |
| 2025-11-17 | Scott Randal W. | +10,000 | $16.75 | $167,500 |
| 2025-11-17 | Trimarchi Thomas | -6,956 | $66.8398 | $464,938 |
| 2025-11-17 | Trimarchi Thomas | -9,978 | $66.1923 | $660,467 |
| 2025-11-16 | Trimarchi Thomas | -21,317 | $66.39 | $1,415,236 |
| 2025-11-16 | Apuli Maricel | -4,781 | $66.39 | $317,411 |
| 2025-11-16 | Kumar Neil | -11,554 | - | - |
| 2025-11-16 | Kumar Neil | -19,599 | - | - |
| 2025-11-16 | Kumar Neil | -33,544 | - | - |
| 2025-11-16 | Kumar Neil | -32,855 | $66.39 | $2,181,243 |
| 2025-11-16 | Kumar Neil | +11,554 | - | - |
| 2025-11-16 | Kumar Neil | +19,599 | - | - |
| 2025-11-16 | Kumar Neil | +33,544 | - | - |
| 2025-11-12 | Valantine Hannah | -25,484 | - | - |
| 2025-11-12 | Valantine Hannah | -25,484 | $66.07 | $1,683,728 |
| 2025-11-12 | Valantine Hannah | +25,484 | $48.45 | $1,234,700 |
| 2025-11-07 | Kumar Neil | -220 | $62.7936 | $13,815 |
| 2025-11-07 | Kumar Neil | -7,546 | $61.8657 | $466,839 |
| 2025-11-07 | Kumar Neil | -12,234 | $61.1298 | $747,862 |
| 2025-11-07 | Kumar Neil | -200 | $62.805 | $12,561 |
| 2025-11-07 | Kumar Neil | -7,308 | $61.8714 | $452,156 |
| 2025-11-07 | Kumar Neil | -12,492 | $61.1401 | $763,762 |
| 2025-11-06 | Kumar Neil | -100 | $64.39 | $6,439 |
| 2025-11-06 | Kumar Neil | -7,371 | $63.5561 | $468,472 |
| 2025-11-06 | Kumar Neil | -12,529 | $62.9088 | $788,184 |
| 2025-11-06 | Kumar Neil | -100 | $64.39 | $6,439 |
| 2025-11-06 | Kumar Neil | -7,324 | $63.5467 | $465,416 |
| 2025-11-06 | Kumar Neil | -12,576 | $62.9108 | $791,166 |
| 2025-11-06 | DANIELS RONALD J | -61,031 | - | - |
| 2025-11-06 | DANIELS RONALD J | -61,031 | $63.7217 | $3,888,999 |
| 2025-11-06 | DANIELS RONALD J | +61,031 | $34.65 | $2,114,724 |
| 2025-10-29 | MCCORMICK FRANK | -43,393 | $69.2358 | $3,004,349 |
| 2025-10-29 | MCCORMICK FRANK | -8,598 | $68.5026 | $588,985 |
| 2025-10-29 | MCCORMICK FRANK | -3,497 | $67.5235 | $236,130 |
| 2025-10-29 | MCCORMICK FRANK | -31,116 | $66.1958 | $2,059,749 |
| 2025-10-29 | MCCORMICK FRANK | -111,755 | $65.4764 | $7,317,315 |
| 2025-10-27 | MCCORMICK FRANK | -1,641 | $65 | $106,665 |
| 2025-10-09 | Kumar Neil | -20,000 | $54.8023 | $1,096,046 |
| 2025-10-09 | Kumar Neil | -20,000 | $54.8023 | $1,096,046 |
| 2025-10-08 | Kumar Neil | -11,295 | $55.0886 | $622,226 |
| 2025-10-08 | Kumar Neil | -8,705 | $54.3883 | $473,450 |
| 2025-10-08 | Kumar Neil | -11,294 | $55.0886 | $622,171 |
| 2025-10-08 | Kumar Neil | -8,706 | $54.3882 | $473,504 |